Fc-Engineered Anti-TNFR Antibodies for Enhanced Agonistic Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-TNFR superfamily member antibodies' agonistic activity is limited by the density of FcγR-expressing cells in the tumor microenvironment, restricting their efficacy in cancer treatment.
Innovation Solution
Engineering antibodies with specific mutations, such as E345R, E430G, and E345R/E430G/S440Y, to enhance agonistic activity independently of FcγR cross-linking, allowing for improved TNFR signaling in environments with insufficient FcγR cell infiltration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNFR superfamily member antibodies are used to stimulate antitumor immunity, then agonistic activity is improved, but efficacy is limited by the density of FcγR-expressing cells in the tumor microenvironment
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations (E345R, E430G, S440Y) in the Fc region of the antibody to alter its binding properties. These mutations change the physical-chemical parameters of the antibody-FcγR interaction, enabling enhanced agonistic activity that is less dependent on FcγR cell density in the tumor microenvironment.
Solution Approach 2:
The patent uses Fc region mutations as an intermediary mechanism to mediate antibody multimerization and enhance agonistic signaling. The mutated Fc region acts as an intermediary that facilitates crosslinking and clustering of TNFR receptors independently of FcγR engagement, thereby bypassing the limitation of FcγR cell density.
2Reliability
If Fc region is engineered to enhance FcγRIIB engagement, then FcγRIIB binding is improved, but agonistic activity becomes dependent on FcγR-expressing cell density
Solution Approach 1:
The patent introduces specific amino acid substitutions (E345R, E430G, S440Y) in the Fc region to change the binding parameters of the antibody. These parameter changes enable the antibody to achieve enhanced agonistic activity through alternative mechanisms that do not rely on FcγR-expressing cell density in the tumor microenvironment.
Solution Approach 2:
Instead of relying on FcγR engagement to achieve agonistic activity, the patent inverts the approach by engineering the Fc region to promote antibody multimerization and TNFR clustering through direct interactions, bypassing the need for FcγR-mediated signaling.
3Reliability
If antibody multimerization is promoted through FcγR crosslinking, then receptor clustering is improved, but therapeutic effectiveness is restricted by FcγR cell availability
Solution Approach 1:
The patent employs Fc region mutations as an intermediary to facilitate antibody multimerization and TNFR receptor clustering through direct Fc-Fc interactions. This intermediary mechanism enables effective receptor clustering and downstream signaling without requiring FcγR-expressing cells, thereby improving therapeutic effectiveness.
Solution Approach 2:
The engineered Fc region enables the antibody to self-multimerize and self-induce receptor clustering through its own structural modifications. The antibody serves its own function of promoting aggregation and signaling without requiring external FcγR-mediated assistance, thereby overcoming the limitation of FcγR cell availability.
Data Source
AI summary
The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.